Pot, Patents, Pharma: SciSparc (SPRC) Leads PRISM Emerging Pharma Index, Trading Up ~ 38%

Today, SciSparc Ltd. (SPRC) announced that the European patent Office has granted it a new patent. This puts SPRC on the path to accomplishing one of its milestones. One of the company’s goals is to increase the safety of cannabinoid treatment while maintaining therapeutic effects which aligns with the recently granted patent.

SPRC is a specialty clinical-stage pharma company focused on developing technologies focused on the cannabinoid pharmaceuticals market. This market is a dynamic and rapidly evolving sector of the pharmaceutical industry. It holds promise for addressing a wide range of medical conditions, but it also faces challenges related to regulations, research, and product standardization. The future growth of this market will depend on ongoing research, regulatory developments, and public acceptance of cannabinoid-based pharmaceuticals.

SPRC is currently the leader in the PRISM Emerging Pharmaceuticals Index. Follow along for more Pharma leaders and laggards. For those who may also be interested in emerging cannabis companies, check out the PRISM Emerging Cannabis Index, as well.